Department of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Office for Infection Control, Asan Medical Center, Seoul, South Korea.
JAMA Netw Open. 2022 May 2;5(5):e2213606. doi: 10.1001/jamanetworkopen.2022.13606.
IMPORTANCE: Data are limited on whether patients with breakthrough COVID-19 infection have the potential to significantly contribute to the spread of SARS-CoV-2. OBJECTIVE: To compare the secondary attack rate and infectious viral shedding kinetics of SARS-CoV-2 between fully vaccinated individuals (breakthrough infection group) and partially or unvaccinated individuals (nonbreakthrough infection group). DESIGN, SETTING, AND PARTICIPANTS: This cohort study assessed secondary transmission by analyzing the epidemiologic data of health care workers, inpatients, and caregivers diagnosed with COVID-19 during hospitalization or residence in a tertiary care hospital between March 1, 2020, and November 6, 2021. To evaluate viral shedding kinetics, the genomic RNA of SARS-CoV-2 was measured using polymerase chain reaction and performed virus culture from daily saliva samples of individuals with mild COVID-19 infected with the Delta variant who were isolated in a community facility in Seoul, South Korea, between July 20 and August 20, 2021. EXPOSURES: COVID-19 vaccination. MAIN OUTCOMES AND MEASURES: The secondary attack rate and infectious viral shedding kinetics according to COVID-19 vaccination status. RESULTS: A total of 173 individuals (median [IQR] age, 47 [32-59] years; 100 female [58%]) with COVID-19 were included in the secondary transmission study, of whom 50 (29%) had a breakthrough infection. Secondary transmission was significantly less common in the breakthrough infection group than in the nonbreakthrough infection group (3 of 43 [7%] vs 29 of 110 [26%]; P = .008). In the viral shedding kinetics study, 45 patients (median age, 37 years [IQR, 25-49 years]; 14 female [31%]) infected with the Delta variant were included, of whom 6 (13%) were fully vaccinated and 39 (87%) were partially or unvaccinated. Although the initial genomic viral load was comparable between the 2 groups, viable virus in cell culture was detected for a notably longer duration in partially vaccinated (8 days after symptom onset) or unvaccinated (10 days after symptom onset) individuals compared with fully vaccinated individuals (4 days after symptom onset). CONCLUSIONS AND RELEVANCE: In this cohort study, although the initial genomic viral load was similar between vaccinated and unvaccinated individuals, fully vaccinated individuals had a shorter duration of viable viral shedding and a lower secondary attack rate than partially vaccinated or unvaccinated individuals. Data from this study provide important evidence that despite the possibility of breakthrough infections, COVID-19 vaccinations remain critically useful for controlling the spread of SARS-CoV-2.
重要性:关于突破性 COVID-19 感染患者是否有可能显著促进 SARS-CoV-2 传播的数据有限。 目的:比较完全接种疫苗的个体(突破性感染组)和部分或未接种疫苗的个体(非突破性感染组)的 SARS-CoV-2 二次感染率和传染性病毒脱落动力学。 设计、设置和参与者:这项队列研究通过分析 2020 年 3 月 1 日至 2021 年 11 月 6 日期间在一家三级保健医院住院或居住期间被诊断为 COVID-19 的医护人员、住院患者和护理人员的流行病学数据,评估二次传播。为了评估病毒脱落动力学,使用聚合酶链反应测量了 SARS-CoV-2 的基因组 RNA,并对 2021 年 7 月 20 日至 8 月 20 日期间在韩国首尔的一个社区设施中隔离的感染 Delta 变异株的轻度 COVID-19 个体的每日唾液样本进行病毒培养。 暴露:COVID-19 疫苗接种。 主要结果和措施:根据 COVID-19 疫苗接种情况评估二次感染率和传染性病毒脱落动力学。 结果:共有 173 名(中位数[IQR]年龄,47[32-59]岁;100 名女性[58%])COVID-19 患者纳入二次传播研究,其中 50 名(29%)发生突破性感染。突破性感染组的二次传播明显少于非突破性感染组(3/43[7%] vs 29/110[26%];P=0.008)。在病毒脱落动力学研究中,纳入了 45 名感染 Delta 变异株的患者(中位年龄 37 岁[IQR,25-49 岁];14 名女性[31%]),其中 6 名(13%)完全接种疫苗,39 名(87%)部分或未接种疫苗。尽管两组的初始基因组病毒载量相似,但部分接种(症状出现后 8 天)或未接种(症状出现后 10 天)个体的活病毒培养可检测到的时间明显长于完全接种疫苗个体(症状出现后 4 天)。 结论和相关性:在这项队列研究中,尽管接种疫苗和未接种疫苗个体的初始基因组病毒载量相似,但完全接种疫苗个体的活病毒脱落时间较短,二次感染率低于部分接种或未接种疫苗个体。这项研究的数据提供了重要证据,表明尽管存在突破性感染的可能性,但 COVID-19 疫苗接种对于控制 SARS-CoV-2 的传播仍然至关重要。
Front Immunol. 2025-2-7
JMIR Public Health Surveill. 2024-9-19
Adv Exp Med Biol. 2024
N Engl J Med. 2022-2-24
N Engl J Med. 2021-12-23
N Engl J Med. 2021-12-9
N Engl J Med. 2021-12-9
N Engl J Med. 2021-12-9
N Engl J Med. 2021-10-28